AbbVie Inc. $ABBV Stock Sold by Hall Laurie J Trustee

Hall Laurie J Trustee lowered its stake in AbbVie Inc. (NYSE:ABBV) by 15.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,655 shares of the company’s stock after selling 2,050 shares during the quarter. Hall Laurie J Trustee’s holdings in AbbVie were worth $3,049,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in ABBV. Corient Private Wealth LP bought a new position in shares of AbbVie in the second quarter worth approximately $559,736,000. Legal & General Group Plc purchased a new stake in shares of AbbVie in the second quarter worth $2,905,952,000. Jupiter Topco LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at $1,560,354,000. Cardano Risk Management B.V. raised its position in shares of AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after purchasing an additional 4,908,260 shares during the period. Finally, Diamant Asset Management Inc. lifted its stake in shares of AbbVie by 21,649.0% during the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after buying an additional 3,654,351 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Price Performance

Shares of AbbVie stock traded up $0.89 during trading on Tuesday, reaching $266.65. 4,500,600 shares of the stock traded hands, compared to its average volume of 6,436,153. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $269.39. The business has a fifty day simple moving average of $258.05 and a two-hundred day simple moving average of $235.01. The company has a market capitalization of $471.11 billion, a price-to-earnings ratio of 75.32, a P/E/G ratio of 1.19 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the business earned $2.97 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong Phase 3 lymphoma results: AbbVie and Genmab reported that Epkinly (epcoritamab) combined with R-CHOP significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma. The combination reduced the risk of disease progression or death by 51% versus R-CHOP alone, potentially positioning Epkinly as a frontline treatment standard and creating a larger commercial opportunity. The companies plan to discuss the results with global regulators. AbbVie and Genmab Epkinly Phase 3 results
• Positive Sentiment: Analysts raise their outlook: Scotiabank lifted its ABBV price target from $280 to $320 and maintained a “sector outperform” rating. HSBC separately outlined a bullish case for a potential $315 target, citing AbbVie’s pipeline and growth prospects. Wall Street’s average recommendation remains equivalent to “Buy,” although analyst optimism is already reflected in the stock’s elevated valuation. Scotiabank raises AbbVie price target
• Positive Sentiment: Pipeline diversification: Coverage highlighted AbbVie’s newly approved Parkinson’s disease pill, described as the first FDA-approved selective D1/D5 therapy, adding another potential growth driver beyond immunology and oncology.
• Neutral Sentiment: Upcoming earnings catalyst: Investors are looking ahead to AbbVie’s third-quarter report, expected later this month. Results and management’s outlook will be important tests for the stock after its substantial rally.
• Negative Sentiment: Lower near-term EPS guidance: AbbVie incorporated $216 million of acquired in-process research and development and milestone expenses into its third-quarter outlook, reducing adjusted EPS guidance to $3.73–$3.77 from the prior range of $3.87–$3.91. Full-year adjusted EPS guidance was also reduced by $0.11 to $13.76–$13.96, creating a modest earnings headwind. AbbVie updates 2026 EPS guidance
• Negative Sentiment: Pricing uncertainty: AbbVie’s participation in a federal 340B rebate pilot ahead of 2027, together with an anticipated Medicare price reduction for Vraylar, could pressure future pricing and margins, though the near-term financial impact remains uncertain.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ABBV shares. Wells Fargo & Company increased their price target on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. BMO Capital Markets boosted their price objective on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Rothschild & Co Redburn upped their price objective on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Oppenheimer increased their target price on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Finally, Piper Sandler lifted their target price on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $273.82.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.